About four years after launch, Orna Therapeutics Inc. signed its second major deal, this time validating the lipid nanoparticle delivery technology it acquired through its Renagade Therapeutics Inc.

Vertex Pharmaceuticals Inc. closed $111.56 below its 52-week high ($519.88), which the company achieved on November 8th.

HBS, CDW, Leidos, SAP, SAS and Vertex are among the companies to list open positions for channel-related roles.

Vertex VERX shares have skyrocketed 107.3% in the past 12 months, outperforming the Zacks Computer Technology sector, Zacks ...

The three-year partnership is another example of Vertex’s interest in improving on Casgevy, its CRISPR medicine for sickle cell and beta thalassemia.

Vertex Pharmaceuticals Inc. will work with a Watertown biotech on new gene-editing therapies for people with sickle cell ...

New research by Security Intelligence has revealed security risks in MLOps platforms including Azure ML, BigML and Google ...

The deal is set to help Vertex’s development of next-generation gene editing therapies for sickle cell disease and ...

Vertex aims to further bolster its gene-editing therapy pipeline by using Orna's lipid nanoparticle delivery technologies during the three-year collaboration.

Vertex Pharmaceuticals (VRTX) is facing technical challenges, with its stock forming a Death Cross and down 15% in 6 months.

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, January 7: NextNav Inc. NN: This positioning, navigation, and timing (PNT) solutions provider ...

Gene-editing kicked off 2024 with a bang in the medical sector but closed the year with a whimper. It started with the FDA ...